There's no way it's a dud. When Chip Clark at Genocea made the remark recently regarding the Admedus hsv 2 vaccine that there was so mush talent at Admedus and he wouldn't bet against them he was simply preparing his constituent's for the inevitable.
Just look at the way it's playing out. Do people really think that the professor and his team are going to be nervously pacing up and down in the lab with their white coats on waiting for the results to come through.
Ann: HSV-2 Phase IIa Results Investor Webinar, page-134
-
- There are more pages in this discussion • 163 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.60 |
Change
-0.100(0.53%) |
Mkt cap ! $357.5M | |||
| Open | High | Low | Value | Volume |
| $18.70 | $18.77 | $18.21 | $664.1K | 35.88K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $18.50 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.69 | 53 | 1 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| AVR (ASX) Chart |